AIM: To delineate the role of pelvic and para-aortic node involvement in @entity1 with optimally cytoreduced (R <=1 cm; R= @entity41 ) @entity43 . @entity1 AND METHODS: Ninety-five consecutive optimally cytoreduced @entity1 with @entity43 underwent stage-related surgery and adjuvant @entity902 -based chemotherapy, with a median follow-up of 53.5 months. All @entity1 underwent systematic lymphadenectomy. On average, 24.7 pelvic and para-aortic lymph nodes were removed per @entity1 (range=1-60 nodes); @entity1 were stratified into three groups to evaluate nodal involvement (ratio of affected to resected nodes): 0: no lymph node @entity3 ; >0-0.5: >0 and fewer than 50% of involved nodes; >0.5-1: more than 50% of nodes involved. Clinical parameters were retrospectively evaluated. RESULTS: Most often, serous histology, histological grade 3 and a node ratio >0- <=0.5 (61.1%) were detected. Complete cytoreduction (R=0 mm) had significant best prognostic impact compared to R>0 mm-1 cm (overall survival: p=0.047, progression-free survival: p<0.001). Nodal involvement was associated with serous histology and grade 3 @entity5 . Best overall survival was associated with a node ratio >0- <=0.5 (p=0.011). A solitary affection of the pelvic or rather para-aortic nodes was detected in 22.1% vs. 16.%, respectively; a combined affection of pelvic and paraaortic nodes were detected in 34.8%. CONCLUSION: The goal is optimal cytoreduction in advanced @entity43 . More extensive pelvic and para-aortic lymphadenectomy seems to play an important role in providing accurate staging in optimally-cytoreduced advanced @entity43 and the node ratio might give prognostic information. Current prospective studies should investigate if these data have therapeutic implications and may be considered in future staging.

Role of Pelvic and Para-aortic Lymph Node @entity3 in Optimally Cytoreduced Advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer', 'stage IIIC ovarian cancer', 'primary stage IIIc ovarian cancer'] @entity41 :: ('MESH:D018365', 'Disease') :: ['residual tumor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity43 :: (MESH:D010051,Disease) :: ['Ovarian Cancer']
